Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases

Oncology Reports

Volumn 20, Issue 2, 2008, Pages 379-384

  Park, Jung Hyun ^a   Kim, Eun Jung ^a   Jang, Hye Yeon ^a   Shim, Heyok ^a   Lee, Kang Kyoo ^a   Jo, Hyang Jeong ^a   Kim, Hwi Jung ^a   Yang, Sei Hoon ^a   Jeong, Eun Taik ^a   Kim, Hak Ryul ^a  

^a Wonkwang University   (South Korea)

Author keywords

Apoptosis; Arsenic trioxide; Lung cancer cells; Mitogen activated protein kinases; Oxidative stress; Sulindac

Indexed keywords

ARSENIC TRIOXIDE; HEME OXYGENASE 1; HISTONE H2AX; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; SULINDAC;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; DNA DAMAGE; ENZYME INHIBITORS; FLOW CYTOMETRY; G1 PHASE; HEME OXYGENASE-1; HISTONES; HUMANS; HYDROGEN PEROXIDE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDATIVE STRESS; OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SULINDAC; TUMOR CELLS, CULTURED;

EID: 48749127647     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000018     Document Type: Article

References (44)

1. Jemal A, Chu KC and Tarone RE: Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst 93: 277-283, 2001.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
3. Antman KH: Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6: 1-2, 2001.
4. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
5. Kim HR, Kim EJ, Yang SH, Jeong ET, Park C, Kim SJ, Youn MJ, So HS and Park R: Combination treatment with arsenic trioxide and sulindac augments its apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. Int J Oncol 28: 1401-1408, 2006.
6. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM and Zheng MH: Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 4: 33-37, 1999.
7. Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 35: 1258-1263, 1999.
8. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6: 4957-4964, 2000.
9. Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 445: 59-62, 1999.
10. Shiff SJ, Qiao L, Tsai LL and Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96: 491-503, 1995.
11. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanism underlying non-steroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998.
12. Milas L: Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 11: 290-299, 2001.
13. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, Whitehead CM, Piazza G, Pamukcu R, Thompson WJ, Alila H, Nelson P and Bunn PA Jr: Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 8: 904-912, 2002.
14. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG and Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94: 2102-2111, 1999.
15. Gupta S, Yel L, Kim D, Kim C, Chiplunkar S and Gollapudi S: Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Mol Cancer Ther 2: 711-719, 2003.
16. Davison K, Cote S, Mader S and Miller WH: Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17: 931-940, 2003.
17. Crissman HA and Steinkamp JA: Cell cycle-related changes in chromatin structure detected by flow cytometry using multiple DNA fluorochromes. Eur J Histochem 37: 129-138, 1993.
18. 2 release from human granulocytes during phagocytosis. I. Documentation, quantitation, and some regulating factors. J Clin Invest 55: 945-955, 1975.
19. Chen YC, Lin-Shiau SY and Lin JK: Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 177: 324-333, 1998.
20. Chung YM, Bae YS and Lee SY: Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. Free Radic Biol Med 34: 434-442, 2003.
21. Fernandes E, Toste SA, Lima JL and Reis S: The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. Free Radic Biol Med 35: 1008-1017, 2003.
22. Oguro T, Hayashi M, Nakajo S, Numazawa S and Yoshida T: The expression of heme oxygenase-1 gene responded to oxidative stress produced by phorone, a glutathione depletor, in the rat liver; the relevance to activation of c-jun n-terminal kinase. J Pharmacol Exp Ther 287: 773-778, 1998.
23. Elbirt KK, Whitmarsh AJ, Davis RJ and Bonkovsky HL: Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. Role of mitogen-activated protein kinases. J Biol Chem 273: 8922-8931, 1998.
24. Loft S and Poulsen HE: Cancer risk and oxidative DNA damage in man. J Mol Med 74: 297-312, 1996.
25. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y and Bonner WM: Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 275: 9350-9355, 2000.
26. Sekiguchi M and Tsuzuki T: Oxidative nucleotide damage: consequences and prevention. Oncogene 21: 8895-8904, 2002.
27. Bernstam L and Nriagu J: Molecular aspects of arsenic stress. J Toxicol Environ Health B Crit Rev 3: 293-322, 2000.
28. Daum G, Pham J and Deou J: Arsenite inhibits Ras-dependent activation of ERK but activates ERK in the presence of oncogenic Ras in baboon vascular smooth muscle cells. Mol Cell Biochem 217: 131-136, 2001.
29. Minami T, Adachi M, Kawamura R, Zhang Y, Shinomura Y and Imai K: Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin Cancer Res 11: 5248-5256, 2005.
30. Fiers W, Beyaert R, Declercq W and Vandenabeele P: More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 18: 7719-7730, 1999.
31. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
32. Seger R and Krebs EG: The MAPK signaling cascade. FASEB J 9: 726-735, 1995.
33. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K and Karin M: The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15: 6269-6279, 1996.
34. Sun Y and Sinicrope FA: Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol Cancer Ther 4: 51-59, 2005.
35. Keyse SM and Tyrrell RM: Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 86: 99-103, 1989.
36. Lautier D, Luscher P and Tyrrell RM: Endogenous glutathione levels modulate both constitutive and UVA radiation/hydrogen peroxide inducible expression of the human heme oxygenase gene. Carcinogenesis 13: 227-232, 1992.
37. Lee TC and Ho IC: Differential cytotoxic effects of arsenic on human and animal cells. Environ Health Perspect 102: 101-105, 1994.
38. Zhang J and Piantadosi CA: Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J Clin Invest 90: 1193-1199, 1992.
39. Ashok BT, Ahmad J, Qadri A and Ali R: Anti-ROS-DNA monoclonal antibody as molecular probe for oxidative DNA damage. Biochem Mol Biol Int 43: 1219-1229, 1997.
40. Elliott B and Jasin M: Double-strand breaks and translocations in cancer. Cell Mol Life Sci 59: 373-385, 2002.
41. Masuda A and Takahashi T: Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis. Oncogene 21: 6884-6897, 2002.
42. Mills KD, Ferguson DO and Alt FW: The role of DNA breaks in genomic instability and tumorigenesis. Immunol Rev 194: 77-95, 2003.
43. West MH and Bonner WM: Histone 2A, a heteromorphous family of eight protein species. Biochemistry 19: 3238-3245, 1980.
44. Thatcher TH and Gorovsky MA: Phylogenetic analysis of the core histones H2A, H2B, H3 and H4. Nucleic Acids Res 22: 174-179, 1994.